Background/aim: To determine the therapeutic superiority of addition of intratympanic steroid or hyperbaric oxygen therapy to systemic steroid treatment in idiopathic sudden sensorineural hearing loss initial treatment and to evaluate long-term results of salvage treatment.
1.INTRODUCTION
Idiopathic sudden sensorineural hearing loss (ISSHL) is an unfrequent otologic emergency which is defined as loss of more than 30 dB in at least 3 contagious frequencies within 3 days.
Up to date ISSHL etiology, pathogenesis and treatment have not been clarified exactly.
Systemic steroids (SS) are the most frequently used treatment modality that has been shown by several clinical trials [1, 2] . There are still controversies in administration route, dosage, duration of therapy and selection of corticosteroid type. After the first attempt of intratympanic steroid (ITS) usage in inner ear disease in 1991, three different protocols of ITS usage in ISSHL has been described as initial monotherapy, initial adjunctive to SS and salvage therapy. However, dosage, type and timetable are still unclear today [3, 4] . Hyperbaric oxygen therapy (HBOT) is frequently used as an alternative modality to steroids in the treatment of ISSHL which diminishes cochlear hypoxia, edema and damage. Efficacy in ISSHL treatment is still conflictive and it is generally accepted as salvage therapy [5] [6] [7] .
To get more superior therapeutical results, combination modalities such as the addition of ITS or HBOT to SS, have been tried by many authors. But, various and conflictive results have been obtained [2, [8] [9] [10] [11] . Thus, Gau and Liu performed a meta-analysis with 8 studies about the combination of ITS to SS [12] . They reported better outcomes in pure tone treshold average (PTTA) scores particularly in severe-profound hearing loss patients with the combination of ITS. Moreover, there are 2 systematic reviews performed with 19 and 16 trials about combination of HBOT to SS. Both of them suggested the HBOT combination to SS especially in severe-profound hearing loss [13, 14] .
In literature, most of the studies compared the success rates of SS monotherapy with either ITS or HBOT combination. On the other hand, only 2 studies are comparing the addition of ITS with the addition of HBOT to SS. Sukuzi et al. [15] concluded that combination of ITS with SS was superior to HBOT addition in terms of recovery rate. However, Toroslu et al. [16] found no significant differences between the 2 combination protocols. Thus, we conducted this study firstly, to show the therapeutic superiority of ITS or HBOT combination as initial therapy and secondly to exhibit the short-term and the long-term prognosis after the salvage treatment of the ISSHL patients.
2.MATERIALS AND METHODS
This clinical study with ISSHL patients was conducted in a tertiary referral center after the approval of local ethics committee (No:42/13:06.11.2017) The recordings of these patients who were managed with different types treatment protocols between 2012 and 2016 were evaluated retrospectively.
Inclusion Criteria
1. Patients who were hospitalized due to ISSHLwith the symptom duration less than 30 days.
2. Patients who completed the treatment protocols properly.
3. Patients who have the recordings of the pretreatment and posttreatment audiogram, otolaryngologic examination, magnetic resonance imaging with contrast.
Exclusion Criteria
1. Symptom duration longer than 30 days. According to the inclusion and exclusion criteria, the patients were divided into 3 groups as initial treatment. Group 1 was the steroid monotherapy group that composed of SS plus 5 mg/kg intravenous dextran for 5 days plus 3x1600 mg oral piracetam till the end of therapy.
Previous history of
Methylprednisolone was used as a single bolus dosage of 250 mg for first day, 150 mg for the second day and 100 mg for the third day. After third day, 1 mg/kg/d oral methylprednisolone was started and tapered 16 mg every 3 days. Group 2 was composed of group 1 treatment protocol plus simultaneously 5 doses of 2 mg intratympanic dexamethasone (0.5 ml from 4 mg/ml ampul form) once in every 2 days. Group 3 included group 1 treatment protocol plus 120 minutes of 2,5-atmosphere HBOT for 20 consecutive days. (Table 1) . The clinical records of the patients without complete recovery which were directed to salvage treatment were also analyzed. Group 1 patients were treated with ITS protocol and then HBOT if there were no complete recovery. In group 2 and group 3 patients, HBOT and ITS protocols were added as salvage respectively. The pre and post-salvage audiograms were compared. Finally, the last audiologic data of the patients after the follow-up was examined and compared with the post salvage results.
Statistical Analyses
Statistical analyses were performed with the IBM SPSS for Windows Version 22.0.
Numerical variables were summarized as mean ± standard deviation or median [minimummaximum]. Categorical variables were given as frequencies and percentages. Categorical variables were compared by chi-square test. Normality of the continuous variables was evaluated by the Kolmogorov Smirnov test. Homogeneity of variances was tested by Levene test. Differences between the groups according to continuous variables were determined one way ANOVA or Kruskal Wallis test as appropriate. A p-value less than 0.05 was considered significant.
3.RESULTS
The study group was composed of 96 patients. Every 3 groups had 32 patients. Patient characteristics according to age, sex, affected ear side, presence of vertigo and tinnitus symptoms, history of systemic illness such as diabetes mellitus and hypertension, upper respiratory tract disease history, and time duration between onset of symptom and therapy were shown in Table 2 . According to these characteristics, there was no statistically significant difference, so there was no heterogenicity in each group. The groups were also investigated according to pretreatment audiologic data. The level of hearing loss of each patient was categorized according to initial PTTA at 500, 1000, 2000 and 4000 Hz and classified into mild (26-40 dB), moderate (41-60 dB), severe (61-80 dB) and profound (>80 dB) hearing loss. Also, PTTA and SDS were calculated in each group. All groups were statistically homogenous concerning initial audiologic assessment which was shown in Table 3 . The audiologic evaluation after initial treatment was evaluated and PTTA of all patients in each groups were categorized according to Furuhashi criteria and the results were shown in Table 4 . There was no statistically significant difference in posttreatment audiologic results between the groups (p:0,66). Complete recovery and marked improvement were accepted as successful treatment which was 24 (75%), 18 (56,3%) and 19 (59.4%) patients in groups 1, 2 and 3 respectively and there was no significant difference between groups (p:0,248) ( Table 5) .
The overall success rate was 63,5% and overall complete recovery rate after initial treatment was found to be 50% regardless of the type of regimens in 96 patients. The patients without complete recovery (n:48, 50%) were directed to salvage therapy. Only 40 of these patients audiologic results were available at the end of salvage treatment. Presalvage and post-salvage PTTA results were evaluated and patients were categorized according to Furuhashi criteria. Only in 3 patients (2 patients with complete recovery, 1 patient with marked improvement) successful results after salvage treatment was obtained in 40 patients (7,5%). Thus, the success rate was 58% after the completion of the initial and salvage treatment in 88 patients. The audiograms of these 40 patients were reanalyzed with a mean of 36,5 (±18.61) months of follow-up after the end of salvage treatment. There was no statistically significant difference in PTTA not only between presalvage and post salvage but also between post salvage and long-term follow-up (p:0.121, p:0.223 respectively) ( Table 6 ).
Long-term follow-up spontaneous recovery rate after the salvage therapy with a mean follow up of 36,5 months was 0%. 
4.DISCUSSION
Due to the lack of proven definitive etiopathogenetic mechanisms in ISSHL, no standard 100% curative treatment modality has been established yet. The recovery rate of patients with ISSHL regardless of therapy regimens was shown to be up to 89% [18] . There are several prognostic factors influencing the hearing outcome. Out of the type of treatment protocol, success also depends on age, presence of tinnitus, initial hearing level, smoking, the shape of audiometry curve and the time interval between onset of symptom and beginning of therapy [19] [20] [21] . Furthermore, there is still a lack of the consensus in evaluation criteria of hearing the outcome. Pure tone audiometry threshold levels in dB values, SDS or categorizations according to hearing improvement such as Furuhashi criteria are generally used for hearing outcome assessment [22] . Another point to mention is that there is still no uniform standards in dosage and duration of protocols regardless of any sort of therapy. Because of these reasons, different and conflicting results have been revealed in literature. Although Cinamon et al. [23] found that there were no significant difference in recovery rate between SS treatment and placebo, Wilson et al. [24] reported significant improvement of SS against placebo. In our study, the groups were homogenous according to prognostic factors and the complete recovery rate was the highest in SS monotherapy group (59,4% vs 43,8% and 46,9%) In the group 1, better but insignificant pretreatment PTTA and SDS levels may lead to higher success rate with respect to other groups.
Systemic usage of steroid has some limitations due to serious side effects such as peptic ulcer, glaucoma, uncontrolled diabetes mellitus, hypertension, osteoporosis and avascular necrosis of femur. So, the intratympanic route has become popular both in salvage and initial treatment of ISSHL. Successful results were shown by several studies both in initial treatment and salvage therapy after SS [18, [24] [25] [26] [27] . In the present study, ITS combination to SS as initial treatment resulted in a rate of 43,8% of complete recovery. In literature, initial ITS treatment in ISSHL has a success range between 55%-80% [28] . The recommended time duration between onset and ITS therapy is less than 10 days to improve the outcome [22] . Although our mean duration of initiation of ITS therapy was 5,2 days, we couldn't able to achieve better results with the addition of ITS. The addition of ITS to SS has revealed different results in the literature. Battaglia et al. [25] and Gundogan et al. [29] reported better hearing improvement in ITS combination to SS according to PTTA. On the other hand, Baysal et al. [30] and Koltsidopoulos et al. [31] concluded no superior hearing improvement of ITS combination to SS.
The usage of HBOT as an initial treatment of ISSHL was investigated by several authors.
Cekin et al. [32] and Alimoglu et al. [33] compared HBOT plus oral steroids with oral steroid alone treatment retrospectively and found no significant differences between them. Whereas, Topuz et al. [5] and Fujimura et al. [34] reported significant improvement in hearing outcome with HBOT at the initial treatment of ISSHL. Thus there is still controversies in effectiveness of HBOT in initial management. Our study showed that addition of HBOT to SS initial treatment did not result in better hearing outcome with respect to SS monotherapy.
There are only 2 studies comparing ITS combination with HBOT combination to SS as initial treatment in the literature. Suzuki et al. [15] compared 174 patients of ITS plus SS with 102 patients of HBOT plus SS retrospectively. Total recovery (cure) rate was 29,3% and 21,6% with ITS and HBOT combination respectively which was not statistically significantly different. Although the group numbers were much more than our study, the groups were not homogenous according to initial hearing level and presence of vertigo and there was no control group as SS monotherapy. They concluded that ITS addition has probably higher recovery rate than HBOT addition. Toroslu et al. [16] analyzed the combination of ITS and HBOT to SS with 90 patients retrospectively. The study consisted of 4 groups: group 1 oral steroid, group 2 oral steroid+ITS, group 3 oral steroid+HBOT and group 4 ITS. The overall complete recovery rate of 90 patients was 32,2% which was lower than in our study. They compared the mean hearing gain in dB instead of recovery rate. There was no statistically significant difference in hearing gain within subgroups. Our result was similar with the aforementioned 2 studies that neither İTS nor HBOT addition to SS had more superior recovery rate in ISSHL initial treatment.
It is important to establish the clinical progress and long-term prognosis of ISSHL.
Intratympanic steroids and HBOT are commonly used as salvage treatment after SS therapy failure and various results have been revealed [20, 35] . Most of the patients recover within the first month of therapy [36, 37] . In a retrospective study, delayed recovery (21.8%) occurred after the first month of discharge and the complete recovery rate was 4.6% [37] . In our study, the complete recovery rate was found to be 5% (2 patients) after salvage therapy. As hearing recovery generally occurs within the first month of therapy, treatment should be done within the first 30 days to gain maximal hearing outcome. Although salvage group number (40 patients) was not large enough, the present study showed that there were no significant spontaneous recovery or deterioration in PTTA after the salvage treatment with a mean follow-up of 36.5 months.
This study has some limitations. Due to the low incidence of ISSHL, the number of patients in this retrospective study was not large enough and there was no placebo subgroup. Secondly, a smoking habit which is a poor prognostic factor was not evaluated in patient characteristics.
Thirdly, there was no hearing outcome analysis with respect to pretreatment hearing loss degree. Lastly, posttreatment levels of SDS and frequency-specific pure tone tresholds and mean hearing gain in dB were not evaluated in the assessment of outcome.
5.CONCLUSION
Addition of ITS or HBOT to SS for ISSHL initial treatment did not get statistically significant therapeutic superiority and improvement. Furthermore, the efficacy in hearing improvement of salvage treatment in ISSHL is still limited. No spontaneous recovery occurs after the end of salvage treatment during long-term follow-up. Thus, for ISSHL and many inner ear disease, cochlea is still a mysterious locked box in which definitive pathogenesis has not been clearly explored yet. Upon several types of treatment modalities, only steroids and hyperbaric oxygen were shown to be effective in ISSHL. Yet there is no alternative treatment protocol superior to these. New regimens are supposed to be introduced after clarification of definitive etiopathogenesis by the help of studies in the future. 
